Literature DB >> 19758398

Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study.

H L Yilmaz1, R D Yildizdas, Y Sertdemir.   

Abstract

BACKGROUND: Vomiting as a consequence of gastroenteritis frequently occurs in children. It is still debatable whether vomiting should be treated with antiemetic drugs. AIM: To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis.
METHODS: A randomized, double blind, placebo-controlled trial was performed in our emergency departments. Children, aged 5 months to 8 years, were randomized to receive either ondansetron 0.2 mg/kg or placebo at 8h intervals. The primary outcome measure was the frequency of emesis during an 8-h-period after enrollment.
RESULTS: A hundred and nine patients were enrolled; 54 received placebo and 55 received ondansetron. As compared with the children who received placebo, children who received ondansetron were less likely to vomit both during the first 8-h follow-up in the emergency department [relative risk (RR): 0.33, 95% CI: 0.19-0.56, NNT: 2, 95% CI: 1.6-3.5], and during the next 24-h follow-up (RR: 0.15, 95% CI: 0.07-0.33, NNT: 2, 95% CI: 1.3-2.1).
CONCLUSION: Ondansetron may be an effective and efficient treatment that reduces the incidence of vomiting from gastroenteritis during both the first 8 h and the next 24 h, and is probably a useful adjunct to oral rehydration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19758398     DOI: 10.1111/j.1365-2036.2009.04145.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Letters to the editor.

Authors:  Mohamed Eltorki
Journal:  Paediatr Child Health       Date:  2014-11       Impact factor: 2.253

Review 2.  Gastroenteritis in children.

Authors:  Jacqueline R Dalby-Payne; Elizabeth J Elliott
Journal:  BMJ Clin Evid       Date:  2011-07-26

Review 3.  Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.

Authors:  Zbys Fedorowicz; Vanitha A Jagannath; Ben Carter
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

4.  Management of a child with vomiting.

Authors:  Sunit C Singhi; Ravi Shah; Arun Bansal; M Jayashree
Journal:  Indian J Pediatr       Date:  2013-01-23       Impact factor: 1.967

5.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

6.  Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting.

Authors:  Marie Hagbom; Claudia Istrate; David Engblom; Thommie Karlsson; Jesus Rodriguez-Diaz; Javier Buesa; John A Taylor; Vesa-Matti Loitto; Karl-Eric Magnusson; Håkan Ahlman; Ove Lundgren; Lennart Svensson
Journal:  PLoS Pathog       Date:  2011-07-14       Impact factor: 6.823

7.  Acute gastroenteritis: from guidelines to real life.

Authors:  Chung M Chow; Alexander Kc Leung; Kam L Hon
Journal:  Clin Exp Gastroenterol       Date:  2010-07-15

Review 8.  The effect of antiemetics in childhood gastroenteritis.

Authors:  Jai K Das; Rohail Kumar; Rehana A Salam; Stephen Freedman; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

9.  Randomized study of ondansetron versus domperidone in the treatment of children with acute gastroenteritis.

Authors:  Sanguansak Rerksuppaphol; Lakkana Rerksuppaphol
Journal:  J Clin Med Res       Date:  2013-10-12

10.  Ondansetron treatment reduces rotavirus symptoms-A randomized double-blinded placebo-controlled trial.

Authors:  Marie Hagbom; Daniel Novak; Malin Ekström; Younis Khalid; Maria Andersson; Magnus Lindh; Johan Nordgren; Lennart Svensson
Journal:  PLoS One       Date:  2017-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.